Published in:
Open Access
01-12-2019 | Anakinra | Letter
Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
Authors:
Giulio Cavalli, Alessandro Tomelleri, Giacomo De Luca, Corrado Campochiaro, Charles A. Dinarello, Elena Baldissera, Lorenzo Dagna
Published in:
Arthritis Research & Therapy
|
Issue 1/2019
Login to get access
Excerpt
Adult-onset Still’s disease (AOSD) is a rare condition characterized by fever, arthritis, skin rash, and multi-organ inflammation. The pathogenesis is mediated by the pro-inflammatory cytokine interleukin (IL)-1β, as confirmed by the clinical efficacy of selective blockade. Anakinra, a recombinant inhibitor of the IL-1β receptor, currently represents the cornerstone of biologic therapy [
1]. …